Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Business Combination - Summary of Total Fair Value Consideration (Details) - USD ($) $ in Thousands		3 Months Ended
	Dec. 12, 2018	Mar. 31, 2020
Business Acquisition [Line Items]
Total fair value consideration		$ 527,754
Keryx Biopharmaceuticals, Inc.
Business Acquisition [Line Items]
Total fair value consideration	$ 527,754
Keryx Biopharmaceuticals, Inc. \| Akebia Shares
Business Acquisition [Line Items]
Total fair value consideration	516,492
Keryx Biopharmaceuticals, Inc. \| Akebia RSUs
Business Acquisition [Line Items]
Total fair value consideration	304
Keryx Biopharmaceuticals, Inc. \| Akebia Stock Options
Business Acquisition [Line Items]
Total fair value consideration	$ 10,958